Literature DB >> 2988769

Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer.

W K Evans, R Makuch, G H Clamon, R Feld, R S Weiner, E Moran, R Blum, F A Shepherd, K N Jeejeebhoy, W D DeWys.   

Abstract

During a randomized trial of total parenteral nutrition (TPN) in patients with small cell lung cancer, we evaluated the short- and long-term effects of 4 weeks of TPN on nutritional assessment parameters. All 119 patients who were accrued to the study received the same chemotherapy and radiotherapy protocol which extended over a 1-year period: 57 patients received TPN; and 62 served as controls. At base line, patients with greater than 5% pretreatment weight loss had significantly lower levels of serum albumin, total iron-binding capacity, and creatinine/height index. TPN administration led to a significant increase in mean caloric intake and weight compared with controls (P less than 0.0001). In the short-term study, body fat, as measured by triceps skinfold thickness, was maintained, and there was a small increase in arm muscle circumference. Serum albumin and hematocrit decreased but promptly returned to pretreatment levels when TPN was stopped. There were no long-term differences in any of the nutritional assessment parameters between the two groups.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2988769

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  Total parenteral nutrition prevents further nutritional deterioration in patients with cancer cachexia.

Authors:  F Bozzetti; M Ammatuna; S Migliavacca; M G Bonalumi; G Facchetti; A Pupa; G Terno
Journal:  Ann Surg       Date:  1987-02       Impact factor: 12.969

2.  Colon 26 adenocarcinoma (C26)-induced cancer cachexia impairs skeletal muscle mitochondrial function and content.

Authors:  Daria Neyroud; Rachel L Nosacka; Andrew R Judge; Russell T Hepple
Journal:  J Muscle Res Cell Motil       Date:  2019-04-03       Impact factor: 2.698

Review 3.  Understanding cancer-induced cachexia: imaging the flame and its fuel.

Authors:  Marie-France Penet; Paul T Winnard; Michael A Jacobs; Zaver M Bhujwalla
Journal:  Curr Opin Support Palliat Care       Date:  2011-12       Impact factor: 2.302

4.  Insulin and acivicin improve host nutrition and prevent tumor growth during total parenteral nutrition.

Authors:  W T Chance; L Cao; J E Fischer
Journal:  Ann Surg       Date:  1988-10       Impact factor: 12.969

5.  Methylarginine metabolites are associated with attenuated muscle protein synthesis in cancer-associated muscle wasting.

Authors:  Hawley E Kunz; Jessica M Dorschner; Taylor E Berent; Thomas Meyer; Xuewei Wang; Aminah Jatoi; Rajiv Kumar; Ian R Lanza
Journal:  J Biol Chem       Date:  2020-10-01       Impact factor: 5.157

Review 6.  Neuropeptides in the pathophysiology and treatment of cachexia.

Authors:  Stephanie M Krasnow; Daniel L Marks
Journal:  Curr Opin Support Palliat Care       Date:  2010-12       Impact factor: 2.302

Review 7.  Nutrition support in hospitalised adults at nutritional risk.

Authors:  Joshua Feinberg; Emil Eik Nielsen; Steven Kwasi Korang; Kirstine Halberg Engell; Marie Skøtt Nielsen; Kang Zhang; Maria Didriksen; Lisbeth Lund; Niklas Lindahl; Sara Hallum; Ning Liang; Wenjing Xiong; Xuemei Yang; Pernille Brunsgaard; Alexandre Garioud; Sanam Safi; Jane Lindschou; Jens Kondrup; Christian Gluud; Janus C Jakobsen
Journal:  Cochrane Database Syst Rev       Date:  2017-05-19

Review 8.  Cancer cachexia.

Authors:  M J Tisdale; S A Beck
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov

Review 9.  Cancer cachexia: understanding the molecular basis.

Authors:  Josep M Argilés; Sílvia Busquets; Britta Stemmler; Francisco J López-Soriano
Journal:  Nat Rev Cancer       Date:  2014-10-09       Impact factor: 60.716

10.  Cancer cachexia is regulated by selective targeting of skeletal muscle gene products.

Authors:  Swarnali Acharyya; Katherine J Ladner; Lori L Nelsen; Jeffrey Damrauer; Peter J Reiser; Steven Swoap; Denis C Guttridge
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.